CD79A: a protein that controls how B cells turn on
CD79A as a molecular switch regulating B cell activation
Researchers are studying whether the protein CD79A acts as a switch that controls B cell activity to help people with autoimmune conditions and improve antibody responses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11366132 on NIH RePORTER |
What this research studies
This project looks at how CD79A helps recruit a regulatory enzyme (SHIP-1) that can quiet B cell signaling. Scientists will use lab-grown immune cells, molecular tests, and animal models to see how changes in CD79A affect antibody production and self-reactivity. The team aims to pinpoint the exact molecular interactions that keep potentially harmful B cells in check. Findings may also use patient-derived samples to connect basic mechanisms to human autoimmune disease.
Who could benefit from this research
Good fit: People with B cell–driven autoimmune diseases (for example lupus or certain antibody-mediated conditions) or those willing to donate blood samples for research would be most relevant.
Not a fit: Patients without B cell–related conditions or those seeking immediate treatment changes are unlikely to get direct benefit from this basic science project.
Why it matters
Potential benefit: If successful, this work could reveal new targets or biomarkers to prevent or reduce harmful B cell activity in autoimmune diseases and improve vaccine or antibody responses.
How similar studies have performed: Prior studies have shown SHIP-1 helps restrain autoreactive B cells, but focusing on CD79A as the specific docking switch is a newer and mostly experimental approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Getahun, Andrew — University of Colorado Denver
- Study coordinator: Getahun, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.